2. Search Result
Search Result
Results for "

irinotecan

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

6

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16562
    Irinotecan
    Maximum Cited Publications
    50 Publications Verification

    (+)-irinotecan; CPT-11; VAL-413(free base)

    		 Topoisomerase Autophagy Cancer
    Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan
  • HY-16562A
    Irinotecan hydrochloride
    Maximum Cited Publications
    50 Publications Verification

    (+)-irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan hydrochloride
  • HY-16568
    Irinotecan hydrochloride trihydrate
    Maximum Cited Publications
    50 Publications Verification

    (+)-irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate
  • HY-16562S1
    Irinotecan-d10 hydrochloride

    		Isotope-Labeled Compounds Topoisomerase Autophagy Cancer
    Irinotecan-d10 (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan-d10 hydrochloride
  • HY-16562S
    Irinotecan-d10

    (+)-irinotecan-d10; CPT-11-d10; VAL-413-d10

    		 Topoisomerase Autophagy Cancer
    Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan-d10
  • HY-131174
    8-Ethyl Irinotecan

    		Biochemical Assay Reagents Others
    8-Ethyl Irinotecan (compound H) is a impurity of Irinotecan hydrochloride (HY-16562A) .
    8-Ethyl Irinotecan
  • HY-16562R
    Irinotecan (Standard)

    		Topoisomerase Autophagy Cancer
    Irinotecan (Standard) is the analytical standard of Irinotecan. This product is intended for research and analytical applications. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan (Standard)
  • HY-16568R
    Irinotecan hydrochloride trihydrate (Standard)

    		Topoisomerase Autophagy Cancer
    Irinotecan (hydrochloride trihydrate) (Standard) is the analytical standard of Irinotecan (hydrochloride trihydrate). This product is intended for research and analytical applications. Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate (Standard)
  • HY-16562AR
    Irinotecan (hydrochloride) (Standard)

    		Topoisomerase Autophagy Cancer
    Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan (hydrochloride) (Standard)
  • HY-16562AS
    Irinotecan-d5 hydrochloride

    (+)-irinotecan-d5 hydrochloride; CPT-11-d5 hydrochloride; VAL-413-d5

    		 Autophagy Topoisomerase Isotope-Labeled Compounds Cancer
    Irinotecan-d5 hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan-d5 hydrochloride
  • HY-146269
    11-Desethyl Irinotecan

    		Drug Metabolite Cancer
    11-Desethyl Irinotecan is a camptothecin (CPT) analog and one of the metabolites of irinotecan. It is promising for cancer research .
    11-Desethyl Irinotecan
  • HY-100620
    RPR121056

    APC

    		 Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE .
    RPR121056
  • HY-100620R
    RPR121056 (Standard)

    APC (Standard)

    		 Drug Metabolite Reference Standards Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (Standard) is the analytical standard of RPR121056. This product is intended for research and analytical applications. RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1].
    RPR121056 (Standard)
  • HY-164271
    10-Boc-SN-38

    		Topoisomerase Cancer
    10-Boc-SN-38 is a tert-butyloxycarbonyl (Boc)-protected form of SN-38 (HY-13704). SN-38 is the active metabolite of Irinotecan (HY-16562) .
    10-Boc-SN-38
  • HY-155228
    LK-44

    		Others Inflammation/Immunology
    hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .
    LK-44
  • HY-145396
    PLGA-PEG-NH2

    		Biochemical Assay Reagents Cancer
    PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .
    PLGA-PEG-NH2
  • HY-139909
    CL2E-SN38

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38
  • HY-139909A
    CL2E-SN38 TFA

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38 TFA
  • HY-147388
    hiCE inhibitor-1

    		Cholinesterase (ChE) Metabolic Disease
    hiCE inhibitor-1, a sulfonamide derivative, is a selective human intestinal enzyme (hiCE) inhibitor with a Ki value of 53.3 nM. hiCE inhibitor-1 can be used to improve Irinotecan (HY-16562)-induced diarrhoea .
    hiCE inhibitor-1
  • HY-155181
    hCES2-IN-1

    		Others Cancer
    hCES2-IN-1 (Compound 24) is a reversible and selective hCES2 inhibitor (IC50: 6.72 μM). hCES2-IN-1 reduces the level of hCES2 in living cells. hCES2-IN-1 is effective against Irinotecan (HY-16562)-induced delayed diarrhea and DSS-induced ulcerative colitis .
    hCES2-IN-1
  • HY-16472R
    Sulfacytine (Standard)

    		Antibiotic Bacterial Infection
    Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Sulfacytine (Standard)
  • HY-141436
    Sucrosofate potassium

    Sucrose octasulfate potassium

    		 Biochemical Assay Reagents Cancer
    Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .
    Sucrosofate potassium
  • HY-141436R
    Sucrosofate (potassium) (Standard)

    		Biochemical Assay Reagents Cancer
    Sucrosofate (potassium) (Standard) is the analytical standard of Sucrosofate (potassium). This product is intended for research and analytical applications. Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .
    Sucrosofate (potassium) (Standard)
  • HY-126373
    SN-38 glucuronide

    SN-38G

    		 Drug Metabolite Cancer
    SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide
  • HY-146080
    Antitumor agent-61

    		Apoptosis Cancer
    Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .
    Antitumor agent-61
  • HY-P10783
    BGC0222

    		Peptide-Drug Conjugates (PDCs) Integrin Cancer
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .
    BGC0222
  • HY-126373S1
    SN-38 glucuronide-13C6

    SN-38G-13C6

    		 Isotope-Labeled Compounds Others
    SN-38 glucuronide- 13C6 is the 13C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide-13C6
  • HY-W653919
    SN-38 glucuronide-d3

    		Isotope-Labeled Compounds Drug Metabolite Cancer
    SN-38 glucuronide-d3 is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide-d3
  • HY-173267
    hCES2A-IN-2

    		Carboxylesterase (CES) Metabolic Disease Cancer
    hCES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent hCES2A inhibitor with an IC50 of 0.04 nM. hCES2A-IN-2 covalently binds to hCES2A by specifically targeting the catalytic serine residue (Ser-228). hCES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice .
    hCES2A-IN-2
  • HY-145513
    CL2-MMT-SN38

    		Topoisomerase Cancer
    CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .
    CL2-MMT-SN38
  • HY-153013
    SN38-COOH

    		Drug-Linker Conjugates for ADC Cancer
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis .
    SN38-COOH
  • HY-168516
    FXR/CES2 modulator 1

    		FXR Others
    FXR/CES2 modulator 1 (compound LE-77) is a doul modulator that activates FXR and inhibits CES2. FXR/CES2 modulator 1 effectively mitigates the intestinal toxicity of irinotecan .
    FXR/CES2 modulator 1
  • HY-14871
    Tenifatecan

    SN2310

    		 Topoisomerase Cancer
    Tenifatecan (SN2310) is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan). Tenifatecan (SN2310) possesses anticancer activity .
    Tenifatecan
  • HY-173243
    Val-Ala-PAB-SN38

    		Drug-Linker Conjugates for ADC Cancer
    Val-Ala-PAB-SN38 is a Drug-Linker Conjugates for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor irinotecan .
    Val-Ala-PAB-SN38
  • HY-155034
    Antitumor agent-102

    		Topoisomerase GLUT Cancer
    Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .
    Antitumor agent-102
  • HY-13704
    SN-38
    45+ Cited Publications

    7-Ethyl-10-hydroxycamptothecin

    		 Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38
  • HY-136170
    MC-SN38
    2 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks .
    MC-SN38
  • HY-13704S
    SN-38-d3

    NK012-d3

    		 Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively .
    SN-38-d3
  • HY-13704R
    SN-38 (Standard)

    		Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38 (Standard)
  • HY-12757
    YHO-13177
    2 Publications Verification

    		 BCRP Cancer
    YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .
    YHO-13177
  • HY-159966
    Top/HDAC-IN-3

    		Topoisomerase HDAC Reactive Oxygen Species (ROS) Apoptosis Cancer
    Top/HDAC-IN-3 (Compound 31) is an orally active dual inhibitor of Topoisomerase and HDAC. Top/HDAC-IN-3 increases reactive oxygen species (ROS) levels, leading to DNA damage, thereby inhibiting cancer cell colony formation and migration, inducing cancer cell Apoptosis, and causing cell cycle arrest. In the NSCLC model, Top/HDAC-IN-3 exhibited significant antitumor effects, with a tumor growth inhibition (TGI) of 77.5% at 100 mg/kg, surpassing the efficacy of the HDAC inhibitor SAHA (HY-10221) and the combination of SAHA (HY-10221) with the topoisomerase inhibitor Irinotecan (HY-16562) .
    Top/HDAC-IN-3
  • HY-173397
    β-Glucuronidase-IN-3

    		β-glucuronidase Bacterial Metabolic Disease
    β-Glucuronidase-IN-3 (Compound 49) is a covalent allosteric β-glucuronidase inhibitor. β-Glucuronidase-IN-3 has potent inhibitory activity against Escherichia coli β-glucuronidase (EcGUS) (IC50: 12.9 nM). β-Glucuronidase-IN-3 exerts its inhibitory effect by reversibly covalently modifying the cysteine residues (Cys28, Cys443, and Cys197) of EcGUS. β-Glucuronidase-IN-3 can be used in the study of intestinal microbiota-related diseases, especially to alleviate the toxic side effects of Irinotecan (HY-16562) and nonsteroidal anti-inflammatory drugs (NSAIDs) .
    β-Glucuronidase-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: